Obesity Drugs: December 2006 Archives

Solvay, Bristol obesity drug advances in trials

|

solvayA new anti-obesity drug that works in the same way as Sanofi-Aventis's Acomplia has advanced in clinical trials, triggering a $25 million payment to Belgian drugs, chemicals and plastics maker Solvay.

Solvay said on Friday it had started further Phase II clinical tests of its SLV319 drug following encouraging early results, prompting the payment from its partner Bristol-Myers Squibb Co.

"Clinical and preclinical studies involving this class of drug have shown that blocking the cannabinoid type 1 (CB1) receptor results in reduced food intake," Solvay said in a statement.

The $25 million will be booked into the fourth quarter 2006 figures but Solvay Pharmaceuticals is increasing its R&D and marketing spending by a similar amount.